CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 1.4% – What’s Next?

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares dropped 1.4% during trading on Wednesday . The company traded as low as $0.85 and last traded at $0.8960. Approximately 12,932 shares changed hands during trading, a decline of 52% from the average daily volume of 26,783 shares. The stock had previously closed at $0.9087.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CytoMed Therapeutics in a report on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, CytoMed Therapeutics presently has a consensus rating of “Sell”.

CytoMed Therapeutics Stock Down 1.4%

The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.06. The business’s 50-day simple moving average is $0.94 and its 200-day simple moving average is $1.01.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.